

Minerva at a glance

Minerva Neurosciences is developing a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. This portfolio includes four compounds with mechanisms of action that we believe are first-in-class.

Our mission is to develop differentiated therapies that address significant unmet needs in the treatment of schizophrenia, insomnia, major depressive disorder and Parkinson's disease. Toward that end, we are applying the knowledge, insights and expertise that our team has accumulated over more than 30 years working in clinical facilities and on pre-clinical and clinical research projects.

We are driven by the recognition of the profound human impact, extensive demographic reach and serious financial burden of the diseases we are targeting, and we invite you to visit our website at www.minervaneurosciences.com to learn more about our ongoing efforts in the field of central nervous system disorders.

Management Team

Remy Luthringer, Ph.D., Chief Executive Officer

Richard Russell, President

Geoff Race, Executive Vice President, Chief Financial Officer, and Chief Business Officer

Michael Davidson, M.D., Chief Medical Officer

Joseph Reilly, Senior Vice President and Chief Operating Officer

Fred Ahlholm, Senior Vice President and Chief Accounting Officer

Justine Lalonde, M.D., Senior Vice President, Product Strategy

Jay Saoud, Ph.D., Senior Vice President, Head of Research and Development

Investor Contact

William Boni, Vice President, Investor Relations and Corporate Communications

Company Information

Minerva Neurosciences, Inc. (Nasdaq: NERV)

1601 Trapelo Road, Suite 286
Waltham, MA 02451
(617) 600-7373

Transfer Agent

Computershare Trust Company, Inc.

www.computershare.com

US Phone: +1 877 373 6374

International Phone: +1 781 575 2879

Product Portfolio

Product Candidates	Targeted Diseases	Mechanisms of Action
MIN-101	Schizophrenia	<ul style="list-style-type: none">● 5-HT_{2A} antagonist● Sigma₂ antagonist
MIN-202	Primary Insomnia Major Depressive Disorder	<ul style="list-style-type: none">● Selective Orexin₂ antagonist
MIN-117	Major Depressive Disorder	<ul style="list-style-type: none">● 5-HT_{1A}● 5HT transporter<ul style="list-style-type: none">● Alpha-1a, b● Dopamine transporter● 5-HT_{2A} antagonist
MIN-301	Parkinson's Disease	<ul style="list-style-type: none">● Neuregulin 1β1 activating ErbB4